Navigation Links
Phase 2a Diarrhea Predominant Irritable Bowel Syndrome Results from,2006 Presented at Digestive Disease Week in Washington, D.C.

SOUTH SAN FRANCISCO, Calif., May 23, 2007 /PRNewswire-FirstCall/ -- Napo Pharmaceuticals, Inc., , which focuses on the development and commercialization of proprietary pharmaceuticals for the global marketplace in collaboration with local partners, announced that Trine Pharmaceuticals, Inc. ("Trine") is presenting a poster detailing the results of a Phase 2a study conducted in 2006 for crofelemer for diarrhoea predominant irritable bowel syndrome (d-IBS) today at Digestive Disease Week in Washington, D.C. Trine licensed crofelemer for the d-IBS indication from Napo in June 2004. Trine has worldwide development and commercialization rights to crofelemer for d-IBS. The objective of the trial was to evaluate the safety and efficacy of crofelemer in men and women with d-IBS.

The trial was designed as a randomized double-blind placebo-controlled, dose-ranging (placebo, 125 mg, 250 mg, and 500 mg bid) study over a 12-week treatment period in 246 patients with d-IBS (Rome II criteria), including both males and females, whose average age was 50 years old.

IBS symptoms (pain, urgency, stool frequency and consistency, and adequate relief) were self-reported by the patients via an interactive voice response system (IVRS). Patients needed to exhibit active disease during the two-week baseline period as defined by a mean daily stool frequency greater than or equal to 2/day, pain score greater than or equal to 1 and stool consistency greater than or equal to 3 (5-point Lickert scale for pain and consistency) to be enrolled. Patients received treatment for 12 weeks followed by a two-week treatment free period.

Results: The 125 mg bid of crofelemer exhibited a consistent response during each month among most efficacy endpoints in women with d-IBS (see table) reaching statistical significance (p<0.05) for pain. Crofelemer had little effect on the stool consistency score, though there was a trend toward redu
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:11/26/2014)... 2014  Cohen, Placitella & Roth, PC is ... purchased Nymox Pharmaceutical Corporation ("Nymox" or "Company") (NASDAQ: ... January 31, 2011 through November 2, 2014 ("Class ... of its officers and directors publically disseminated materially ... 10(b) and 20(a) of the Securities Exchange Act ...
(Date:11/26/2014)... 26, 2014  Over 100 million adults suffer from ... this pain daily. Chronic and acute pain dramatically impacts ... born to fulfill the need for non-surgical, interventional solutions ... On October 28th, a new pain management ... Maryland community.  This new facility boasts cutting ...
(Date:11/26/2014)... 2014 Zynerba Pharmaceuticals , Inc., a ... transdermal synthetic cannabinoid treatments, today announced that the company ... Conference 2014. The conference will be held December 2 ... New York . Zynerba,s Chairman and CEO, ... on Tuesday, December 2. To listen to ...
Breaking Medicine Technology:Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 3New Pain Management Center Opens in Cumberland, Md. 2Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2
(Date:11/27/2014)... According to a recent report by ... break into the surgical robotics market may ... the MIS field dominated by Intuitive. These companies are ... robotics market by 2020. , “The MIS robotic ... CEO and President of iData. “System sales for the ...
(Date:11/27/2014)... Blood-borne pathogens raise the risk of spreading ... in place to counter this. However, it doesn’t seem ... with menstrual blood are taken as seriously. , ... way to handle tampons and menstrual pads while also ... , He then created a prototype of the Sani-M, ...
(Date:11/27/2014)... HealthDay Reporter , WEDNESDAY, Nov. 26, 2014 ... a second language, new research suggests. But anyone who tries ... brain boost, the small study finds. The brain ... Ping Li, co-director of the Center for Brain, Behavior and ... Li said, that "the brain networks of the more successful ...
(Date:11/27/2014)... In order to enable people to adapt to ... easy way to avoid touching a toilet seat and/or lid ... prototype of the patent-pending Toilet Tamer, a device that enables ... lid in a more sanitary manner. It avoids direct contact ... it promotes good hygiene and peace of mind. The portable ...
(Date:11/27/2014)... 27, 2014 Tylenol lawsuits ( http://www.tylenollawsuitcenter.com/ ... injured by the medication are continuing to move forward ... looking ahead to a status conference in December, Bernstein ... Order issued earlier this year, a conference in the ... 10:00 a.m. Items likely to be discussed at the ...
Breaking Medicine News(10 mins):Health News:U.S. Robotic Surgery Market Set to Diversify and Grow: Intuitive Surgical’s ‘da Vinci’ Robot Revenues to Increasingly Rely On Procedures and Services 2Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3
... with manufacturing, unreliable delivery of the drug , , FRIDAY, ... the drug rotigotine help relieve restless legs syndrome (RLS), ... drugs -- which stimulate the body,s dopamine system -- ... and rotigotine is already used to treat Parkinson,s disease. ...
... Appeal Action, EXTON, Pa., May 30 Isolagen(TM), ... it received notice from the staff,of the American Stock ... plan of compliance did not demonstrate its ability,to regain ... Sections 1003 (a)(i)-(iii) of the AMEX Company Guide within ...
... The following is being issued,by the Federation of Clinical ... from 58 countries across the globe, What: FOCIS 2008 ... June 4-Monday, June 9, Where: Boston Marriott Copley Place, ... that improves patient care, Wednesday, June 4, 8:30 ...
... with a certain type of prostate cancer have been ... plus prednisone in an international trial led by Oregon ... The research involved men with androgen-independent prostate cancer that ... prostate and is not longer responding to hormonal therapies. ...
... 16-0, in Favor of Short-Term Treatment of ... 30 GlaxoSmithKline (NYSE: GSK ),today ... Drug Administration,s,Oncology Drugs Advisory Committee (ODAC) unanimously ... risk-benefit profile for,the short-term treatment of patients ...
... HILL, N.C., May 30 Creating an effective ... a new product,s introduction.,A product,s promotion relies heavily ... benchmark companies ensure that they create effective, cross-functional,teams ... a new product., The detailed report provides ...
Cached Medicine News:Health News:Rotigotine Skin Patch May Ease Restless Legs Symptoms 2Health News:Isolagen, Inc. Reports Receipt of Initiation of Delisting Proceedings Notice from Amex 2Health News:Isolagen, Inc. Reports Receipt of Initiation of Delisting Proceedings Notice from Amex 3Health News:World-Renowned Scientists to Lead Immunology Course 2Health News:World-Renowned Scientists to Lead Immunology Course 3Health News:World-Renowned Scientists to Lead Immunology Course 4Health News:OHSU Cancer Institute researchers find novel chemo drug helps treat prostate cancer 2Health News:PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL 2Health News:PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL 3Health News:PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL 4Health News:Managing Cross-Functional Teams for Pharmaceutical Product Commercialization Excellence 2
Validated by decades of research and clinical experience, HFA is the accepted standard of care in glaucoma diagnosis and management. With HFA you can feel confident you're providing the best possible...
... Rapidlab 1200's speed and accuracy allow ... in a timely manner - something ... especially patients. In fact, the Rapidlab ... in just one minute. Its maintenance-free, ...
... challenges. One complete solution. , Increased requirements ... Staff turnover. These are just some of ... challenges that can impact the amount of ... , , You can't afford ...
Dornier Holmium Laser for Urological Procedures...
Medicine Products: